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Objective: Placental site trophoblastic tumor (PSTT) is rare and is characterized by a slow growth. The
objective of this report is to present a case of PSTT associated with irregular vaginal spotting that
occurred 1 year after normal vaginal delivery.
Case Report: This report provides interesting ultrasound, hysteroscopy, and histology ﬁndings of PSTT. It
is difﬁcult to make a clinical diagnosis of PSTT at an early stage. Without the use of immunohistochemical
analysis, PSTT may evade histological detection. An operative hysteroscopy using electrocauterization
reduces active bleeding during the removal of PSTT with markedly engorged tumor vessels.
Conclusion: Transvaginal sonography using color Doppler imaging plays a vital role in identifying re-
sidual PSTT with microscopic inﬁltration to the myometrium and a negative serum b-human chorionic
gonadotropin level.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Placental site trophoblastic tumor (PSTT) derives from inter-
mediate trophoblastic cells. The tumor inﬁltrates the smooth
muscle cells of decidual spiral arterioles during early normal
gestation. PSTT has a malignant potential to invade the myome-
trium or metastasize. PSTT accounts for 0.23e3% of gestational
trophoblastic disease and may arise several months or years after
a normal or abnormal pregnancy [1]. Most patients present with
nonspeciﬁc symptoms and signs at diagnosis, such as abnormal
vaginal bleeding, amenorrhea, mild elevated serum b-human
chorionic gonadotropin (b-HCG) levels (< 1000 mIU/mL in 79% of
cases) [2], and an endometrial or myometrial nodule on trans-
vaginal sonography [3]. The clinical course of PSTT is unpredict-
able. A high b-HCG level and a deep myometrial inﬁltration are
likely to be associated with metastases to the lung, liver, vagina,
intestine, brain, lymph nodes [1,4,5], or even through the placenta
to the fetus [6].and Gynecology, Kaohsiung
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A 30-year-old patient, gravid 1 para 1, presented with irregular
vaginal spotting for several days. She previously gave birth to a
normal baby, weighing 3100 g, through the vagina. The patient was
still breastfeeding her 1-year-old female baby. Her serum b-HCG
level was 15 mIU/mL. Transvaginal sonography revealed an endo-
metrial nodule measuring about 1.3 cm 1.2 cm 1.3 cm, which
contained low-resistance blood ﬂow as seen from color Doppler
imaging. Under a suspicion of residual placental tissues, an opera-
tive hysteroscopy was arranged. Active bleeding occurred during
cervical dilation and impeded further hysteroscopic surgery. After
endometrial curettage, tumor bleeding was controlled by intrave-
nous administration of tranexamic acid and external compression
using SURGICEL FIBRILLAR (Ethicon, Somerville, NJ, USA; oxidized
regenerated cellulose) and an inﬂated Foley balloon inserted into
the uterine cavity.
Histology of the specimens demonstrated products of
conception without evidence of trophoblastic disease. Follow-up
serum b-HCG levels decreased to 5 mIU/mL, but sonography
revealed that the endometrial lesion with low-resistance blood
ﬂow still persisted. Under the impression of focal placenta accreta,
50 mg/m2 of methotrexate was injected through the uterineby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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measurement showed an increase to 9 mIU/mL. Follow-up so-
nography revealed an increase in tumor size and vascularity
(Figures 1A and 1B). Diagnostic hysteroscopy clearly showed a 1.5-
cm tumor with engorged vessels protruding into the uterine
cavity (Figure 1C). After careful dilation of the cervical canal, the
tumor was removed as thoroughly as possible under an operative
hysteroscopy using electrocauterization (Figure 1D). The ﬁnal
histologic report indicated PSTT with up to four mitotic ﬁgures per
high-power ﬁeld (Figure 2A). Immunohistochemical analysis
showed positive staining for human placental lactogen and Ki-67
(Figure 2B). Another follow-up serum b-HCG level showed a
decrease to 1.2 mIU/mL. Positron emission tomography (PET)
revealed neither a residual uterine lesion nor metastatic sites. A
repeated gray-scale transvaginal sonography did not show any
irregularities, but color Doppler imaging identiﬁed low-resistance
trophoblastic ﬂows in the myometrium (Figures 2C and 2D),
consistent with a residual PSTT. After discussionwith the couple, a
laparoscopic-assisted vaginal hysterectomy was performed. A 2.5-
mm residual PSTT inﬁltrating to the myometrium was conﬁrmed
by microscopic examinations and immunohistochemical analysis
(Figure 3).
Discussion
It is difﬁcult to make a clinical diagnosis of PSTT at an early stage
because of mild symptoms, a slight elevation of b-HCG level, a small
lesion in the uterus, and the rarity of PSTT. The suspicion of a
retained placenta or focal placenta accreta tends to be aroused
when clinicians ﬁrst encounter this entity. Invasive mole or
choriocarcinoma is usually associatedwith a high and progressively
growing serum b-HCG level. Of note, the presence of prominentFigure 1. (A) Gray-scale transvaginal sonography displayed an endometrial lesion (L) with
resistance tumor vessels (resistance index of 0.32) in color Doppler imaging. (C) Hysteros
was performed to prevent bleeding during removal of the tumor.vessels and low-resistance trophoblastic ﬂows noted using color
Doppler imaging could not distinguish PSTT from placenta accreta
or residual placental tissues [3,7]. Nevertheless, placenta accreta is
known to be responsive to methotrexate therapy [8].
Without the use of immunohistochemical analysis, PSTT may
also evade histological detection [1]. PSTT is characterized by pos-
itive staining for inhibin, human placental lactogen, cytokeratin,
epidermal growth factor receptor, vascular endothelial growth
factor, and pregnancy-associated major basic protein. Pregnancy-
associated major basic protein is a marker for intermediate tro-
phoblasts and is useful to differentiate PSTT from epithelioid
trophoblastic tumors.
PSTT associated with engorged tumor vessels, partly due to
arteriovenous shunt, is prone to contact bleeding during the
process of cervical dilation and tumor excision. The active
bleeding may obscure the visual ﬁeld of hysteroscopy and make
further procedures of the operative hysteroscopy difﬁcult. After
delicate dilation of the cervix, careful hysteroscopic electro-
cauterization can prevent tumor bleeding and achieve the
removal of the visible PSTT bulging into the uterine cavity. After
tumor removal by operative hysteroscopy, the residual PSTT with
microscopic invasion to the myometrium may not be detectable
using serum b-HCG, PET, or a gray-scale transvaginal sonography.
In this case, transvaginal sonography using color Doppler imaging
seemed to be the most sensitive examination to detect the pres-
ence of residual PSTT.
PSTT is characterized by a slow growth, 61% resistance or
incomplete response to chemotherapy [9], and a tendency to
metastasize through lymphatic pathways. During the early stages,
hysterectomy is the best way to cure PSTT. Although partial resec-
tion of the uterus has been reported in patients with the desire to
preserve fertility [10], it is difﬁcult to guarantee complete excisionmultiple sonolucent areas (arrows), (B) which were found to be composed of low-
copy displayed a mass with obvious tumor vessels (arrows). (D) Electrocauterization
Figure 2. (A) Histology demonstrated multiple giant tumor cells (arrows) inﬁltrating to the muscular layer (m). (B) Immunohistochemical analysis revealed diffuse positive staining
for human placenta lactogen. Transvaginal sonography displayed (C) the endometrium (e) and residual tumor vessels using color imaging, and (D) low-resistance trophoblastic
ﬂows using Doppler imaging.
Figure 3. Microscopic examinations of the uterus conﬁrmed a residual placenta site
trophoblastic tumor (arrows), measuring about 2.5 mm, inﬁltrating the myome-
trium (m).
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usually appears normal to the naked eye and there is no way to
precisely determine the location and extent of tumor invasion to
the myometrium during surgery. In addition, uterine wound
bleeding further complicates the visual ﬁeld in the operative
region.
Chemotherapy is generally used for patients of PSTT with
distant metastases. A metastatic lung nodule measuring 1.3 cm
has been detected using PET [11]. Disappearance of a metastatic
lesion of the lung along with normalization of serum b-HCGlevel, but without changes of the uterine lesion, has been re-
ported after four courses of chemotherapy using etoposide,
methotrexate, actinomycin D, cyclophosphamide, and vincristine
(EMA/CO) [12]. Wedge resection of the lung is needed when
chemotherapy fails [11].
In summary, it is difﬁcult for clinicians to spot the signs and
symptoms of PSTT at an early stage. Without immunohistochemical
analysis, PSTT may evade histological detection. An operative hys-
teroscopy using electrocauterization reduces active bleeding dur-
ing the removal of PSTT with markedly engorged tumor vessels.
Transvaginal sonography using color and Doppler imaging plays a
vital role in identifying residual PSTT with microscopic inﬁltration
to the myometrium and a negative serum b-HCG level.
Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this
article.
References
[1] Bouquet de la Joliniere J, Khomsi F, Fadhlaoui A, Ben Ali N, Dubuisson JB,
Feki A. Placental site trophoblastic tumor: a case report and review of the
literature. Front Surg 2014;1:31.
[2] Papadopoulos AJ, Foskett M, Seckl MJ, McNeish I, Paradinas FJ, Rees H, et al.
Twenty-ﬁve years’ clinical experience with placental site trophoblastic tu-
mors. J Reprod Med 2002;47:460e4.
[3] Zhou Y, Lu H, Yu C, Tian Q, Lu W. Sonographic characteristics of placental site
trophoblastic tumor. Ultrasound Obstet Gynecol 2013;41:679e84.
[4] Lan C, Li Y, He J, Liu J. Placental site trophoblastic tumor: lymphatic spread and
possible target markers. Gynecol Oncol 2010;116:430e7.
[5] Baergen RN, Rutgers JL, Young RH, Osann K, Scully RE. Placental site tropho-
blastic tumor: a study of 55 cases and review of the literature emphasizing
factors of prognostic signiﬁcance. Gynecol Oncol 2006;100:511e20.
[6] Monclair T, Abeler VM, Kaern J, Walaas L, Zeller B, Histrøm C. Placental site
trophoblastic tumor (PSTT) in mother and child: ﬁrst report of PSTT in infancy.
Med Pediatr Oncol 2002;38:187e91.
F.-N. Cho et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 724e727 727[7] Atri M, Rao A, Boylan C, Rasty G, Gerber D. Best predictors of grayscale ul-
trasound combined with color Doppler in the diagnosis of retained products
of conception. J Clin Ultrasound 2011;39:122e7.
[8] Cho FN, Liu CB, Li JY, Chen SN. Complete resolution of diffuse placenta increta
in a primigravida with twin pregnancy: sonographic monitoring. J Clin Ul-
trasound 2011;39:363e6.
[9] Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, et al. Prog-
nostic markers and long-term outcome of placental-site trophoblastic tu-
mours: a retrospective observational study. Lancet 2009;374:48e55.[10] Shen X, Xiang Y, Guo L, Feng F, Wan X, Xiao Y, et al. Fertility-preserving
treatment in young patients with placental site trophoblastic tumors. Int J
Gynecol Cancer 2012;22:869e74.
[11] Nieves L, Hoffman J, Allen G, Currie J, Sorosky JI. Placental-site trophoblastic
tumor with PET scan-detected surgically treated lung metastasis. Int J Clin
Oncol 2008;13:263e5.
[12] Chen Y, Zhang X, Xie X. Clinical features of 17 cases of placental site
trophoblastic tumor. Int J Gynaecol Obstet 2011;115:204e5.
